Accelerating the Translation of Cell Therapy for Type 1 Diabetes

Sept. 22 - 23, 2026 Location Contacts

Event Details Agenda

See Important Visitor Information below regarding an earlier registration deadline for foreign visitors.

Purpose

This public workshop aims to bring together relevant stakeholders to discuss best practices and recommendations to foster the translation of the next generation of cell replacement therapies for type 1 diabetes (T1D). The meeting will include panel discussions and presentations of lessons learned on challenges and strategies specific to the clinical, nonclinical and manufacturing/quality needs to advance future T1D cell replacement therapies.

Planning Committee

Name	Affiliation	Title
Guillermo Arreaza-Rubín	NIDDK	Program Director, Division of Diabetes, Endocrinology, & Metabolic Diseases
Thomas Bollenbach	Advanced Regenerative Manufacturing Institute	Chief Technology Officer
Kevin D’Amour	Independent Consultant
Thomas Eggerman	NIDDK	Program Director, Division of Diabetes, Endocrinology, & Metabolic Diseases
Ellen Feigal	NDA Partners	Partner
Albert Hwa	NIDDK	Program Director, Division of Diabetes, Endocrinology, & Metabolic Diseases
Norma Kenyon	University of Miami	Martin Kleiman Professor of Surgery, Microbiology & Immunology, Biomedical Engineering and Biochemistry & Molecular Biology at the Diabetes Research Institute
Esther Latres	Breakthrough T1D	Senior Vice President, Research
Marjana Marinac	Breakthrough T1D	Associate Vice President, Regulatory Affairs
Chanel Press	Breakthrough T1D	Director, Regulatory Affairs
Michael Rickels	University of Pennsylvania	Professor in Diabetes and Metabolic Diseases
Katherine Szarama	U.S. Food and Drug Administration	Deputy Center Director, Center for Biologics Evaluation and Research

Registration Deadline

September 14, 2026

Important Visitor Information

Due to recent changes to the campus access policy, participants who do not have U.S. Citizenship or Lawful Permanent Resident (Green Card holder) status will need to complete the VisitNIH pre-registration process at least 30 days but no more than 60 days before the start of the event. To avoid missing this deadline, please register for the workshop using the link above as soon as possible and indicate your status. If VisitNIH pre-registration is required, a staff member will reach out to help you through the process.

Day 1: Tuesday, September 22, 2026

8:30 a.m. – 9:00 a.m.: Arrival/Check-in
9:00 a.m. – 9:20 a.m.: Opening Remarks
9:20 a.m. – 9:50 a.m.: Keynote Address
9:50 a.m. – 10:10 a.m.: Q&A
10:10 a.m. – 10:20 a.m.: Coffee Break
10:20 a.m. – 12:40 p.m.: Session 1: Strategies in Nonclinical Studies for Type 1 Diabetes (T1D) Cell Replacement Therapies
(Presentations, Q&A, and Panel Discussions)
12:40 p.m. – 1:50 p.m.: Lunch Break
1:50 p.m. – 3:50 p.m.: Session 2: Challenges and Opportunities in Manufacturing Cell-Replacement Therapies
(Presentations, Q&A, and Panel Discussions)
3:50 p.m. – 4:00 p.m.: Day 1 Wrap-up/Summary
4:00 p.m.: Adjourn

Day 2: Wednesday, September 23, 2026

8:30 a.m. – 9:00 a.m.: Arrival/Check-in
9:00 a.m. – 10:00 a.m.: Perspectives from People with T1D
(Panel Discussion)
10:00 a.m. – 11:25 a.m.: Session 3: Clinical Trial Design Considerations for the Next-generation Therapies
(Presentations, Q&A, and Panel Discussions)
11:25 a.m. – 11:40 a.m.: Coffee Break
11:40 a.m. – 1:00 p.m.: Session 4: Collaborations in an AI-powered Big Data Era
(Presentations, Q&A, and Panel Discussions)
1:00 p.m.: Summary and Closing Remarks

Location

The Lister Hill Center (Building 38A)
Bethesda, MD 20894

Map It

Contacts

Program Contacts
Albert Hwa, Ph.D.
NIDDK

Guillermo Arreaza-Rubin, M.D.
NIDDK

Meeting Logistics
John Hare, M.S.
The Scientific Consulting Group, Inc.

Accelerating the Translation of Cell Therapy for Type 1 Diabetes

Registration

Event Details